Ladenburg Thalmann initiated coverage on Immutep with a new price target
$IMMP
Biotechnology: Pharmaceutical Preparations
Health Care
Ladenburg Thalmann initiated coverage of Immutep with a rating of Buy and set a new price target of $8.30
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/17/2024 | $10.00 | Overweight | CapitalOne |
| 8/3/2023 | $7.00 | Outperform | Robert W. Baird |
| 8/3/2021 | $8.30 | Buy | Ladenburg Thalmann |
| 7/16/2021 | $8.00 | Buy | Maxim Group |
6-K - IMMUTEP Ltd (0001506184) (Filer)
6-K - IMMUTEP Ltd (0001506184) (Filer)
6-K - IMMUTEP Ltd (0001506184) (Filer)
CapitalOne initiated coverage of Immutep with a rating of Overweight and set a new price target of $10.00
Robert W. Baird initiated coverage of Immutep with a rating of Outperform and set a new price target of $7.00
Ladenburg Thalmann initiated coverage of Immutep with a rating of Buy and set a new price target of $8.30
Media Release Centre for Human Drug Research (CHDR) will conduct Phase I trial to evaluate IMP761, a first-in-class LAG-3 agonist antibody designed to restore balance to the immune system and address the underlying cause of autoimmune diseasesCHDR will utilize its unique challenge model that enables insights into IMP761's pharmacological activity early in clinical developmentTrial expected to begin mid-CY2024 SYDNEY, AUSTRALIA, April 18, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has entered into an agreem
Media Release Appointment of Charles River Laboratories ("Charles River") to run Immutep's preclinical toxicology study evaluating the safety and toxicity of IMP761Forms a key step prior to first-in-human trials for this first-in-class LAG-3 agonist antibody designed to treat the underlying cause of multiple autoimmune diseasesCharles River is a highly respected, global provider of drug discovery and non-clinical development solutions operating more than 110 sites across more than 20 countries SYDNEY, AUSTRALIA, May 29, 2023 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LA
Media Release Initiation of integrated Phase II/III AIPAC-003 trial evaluating eftilagimod alpha (efti) and paclitaxel in HER2-neg/low metastatic breast cancer and triple-negative breast cancerPositive final data reported from patients with 2nd line non-small cell lung cancer refractory to anti-PD-(L)1 therapies, including Overall Survival rate of 39% at 21 monthsRandomised TACTI-003 Phase IIb trial has reached 75% enrolment subsequent to quarter end and top line results anticipated in H2 of CY2023Expansion of INSIGHT-003 evaluating triple combination of efti, pembrolizumab and chemotherapy post encouraging initial safety and efficacy in 1st line non-small cell lung cancerSolid cash pos
Media Release Median Overall Survival reaches 35.5 months in first-line treatment of metastatic non-small cell lung cancer patients expressing PD-L1 (TPS >1%), 23.4 months in patients with low PD-L1 expression (TPS 1-49%), and has not been reached in patients with high PD-L1 expression (TPS >50%), exceeding expectationsPromising Overall Survival, Overall Response Rate, Progression Free Survival, and Duration of Response visible across all PD-L1 subgroups (TPS <1%, ≥1%, 1-49%, and ≥50%), differentiates efti in combination with KEYTRUDA® from other chemotherapy-free immuno-oncology combinations in non-small cell lung cancerExceptional durability and quality of responses exhibited through ove
Media Release New updated data from TACTI-002, including more mature Overall Survival data, will be presented during the Mini Oral session on Saturday, October 21st, at 9:05 CESTImmutep to host webcast to discuss ESMO 2023 clinical data on Monday, October 23rd, at 8AM AEDT (Sunday, October 22nd, at 5PM ET) SYDNEY, AUSTRALIA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the publication of abstracts with data from the TACTI-002 and INSIGHT-003 trials in 1st line non-small cell lung cancer (1L NSCLC) at t
SC 13G/A - IMMUTEP Ltd (0001506184) (Subject)
SC 13G/A - IMMUTEP Ltd (0001506184) (Subject)
SC 13G - IMMUTEP Ltd (0001506184) (Subject)
Novel combination with efti has met the trial's primary endpoint of tumour hyalinization/fibrosis in the neoadjuvant setting for patients with resectable soft tissue sarcomaDetailed results are planned for presentation at a future medical meeting SYDNEY, AUSTRALIA, May 27, 2025 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces the investigator-initiated EFTISARC-NEO Phase II trial evaluating eftilagimod alfa (efti) with radiotherapy plus KEYTRUDA® (pembrolizumab) in the neoadjuvant setting for resectable soft tissue sarcoma (STS) has met its primary endpoi
Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L NSCLC)Notably, ~92% of all evaluable patients have PD-L1 TPS <50%, including 43% with PD-L1 below 1 (TPS <1%), who represent an area of high unmet needData demonstrates significant improvement in response rates compared to historical controls, and safety continues to be favourableMulti-centre INSIGHT-003 is evaluating the same immunotherapy/chemotherapy combination used in the pivotal TACTI-004 Phase III in 1L NSCLCAdditional data from INSIGHT-003 is planned for presentation at a medical conference later this year SYDNEY, AUSTRALIA, May 15, 2025 (GLOBE NEWSWIRE) --
Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer patients with PD-L1 CPS <1Mature overall survival data builds on encouraging high response rates with multiple complete responsesPatients with CPS <1 represent a high unmet medical need and have no available treatment options without chemotherapyMeeting with FDA has now been requested to discuss next steps including potential paths to approval SYDNEY, AUSTRALIA, May 05, 2025 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an exc